12:00 AM
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

DCDS4501A: Interim Phase I data

Interim data from 33 heavily pretreated patients in a dose-escalation Phase I trial showed that the recommended Phase II dose of IV DCDS4501A was 2.4 mg/kg given every 21 days. There was 1 patient with a dose-limiting toxicity (DLT) of grade 4 febrile neutropenia and pneumonia. Furthermore, 2 of 4 evaluable patients receiving 2.4 mg/kg IV DCDS4501A had a >80% reduction...

Read the full 284 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >